ZANTAC 75 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zantac 75, and when can generic versions of Zantac 75 launch?
Zantac 75 is a drug marketed by Chattem Sanofi and is included in two NDAs.
The generic ingredient in ZANTAC 75 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zantac 75
A generic version of ZANTAC 75 was approved as ranitidine hydrochloride by SANDOZ on August 29th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZANTAC 75?
- What are the global sales for ZANTAC 75?
- What is Average Wholesale Price for ZANTAC 75?
Summary for ZANTAC 75
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 117 |
Clinical Trials: | 22 |
Patent Applications: | 2,243 |
What excipients (inactive ingredients) are in ZANTAC 75? | ZANTAC 75 excipients list |
DailyMed Link: | ZANTAC 75 at DailyMed |
Recent Clinical Trials for ZANTAC 75
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Spaulding Clinical Research LLC | Phase 1 |
Food and Drug Administration (FDA) | Phase 1 |
Nova Scotia Health Authority | Phase 4 |
US Patents and Regulatory Information for ZANTAC 75
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET, EFFERVESCENT;ORAL | 020745-001 | Feb 26, 1998 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET;ORAL | 020520-001 | Dec 19, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZANTAC 75
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET;ORAL | 020520-001 | Dec 19, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET;ORAL | 020520-001 | Dec 19, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Chattem Sanofi | ZANTAC 75 | ranitidine hydrochloride | TABLET;ORAL | 020520-001 | Dec 19, 1995 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZANTAC 75
See the table below for patents covering ZANTAC 75 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Ireland | 891564 | ⤷ Sign Up | |
Netherlands | 8202659 | ⤷ Sign Up | |
South Korea | 870001431 | ⤷ Sign Up | |
Cyprus | 1077 | AMINOALKYL FURAN DERIVATIVES | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |